General
Preferred name
MITOXANTRONE
Synonyms
MITOXANTRONE HYDROCHLORIDE ()
MITOXANTRONE DIHYDROCHLORIDE ()
mitozantrone ()
mitozantrone dihydrochloride ()
Mitoxantrone 2HCl ()
NSC-301739 ()
CL 232325 ()
CL-232325 ()
DHAQ ()
Novantron ()
Novantrone ()
Mitoxantrone HCl ()
Dihydroxyanthraquinone ()
Mitoxantrone (free base) ()
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl] amino]- ()
Mitroxone ()
Mitoxantrone 2HCl ()
Dhaq diacetate ()
Mitoxantrone (dihydrochloride) ()
MITOXANTRONE70476-82-3 ()
NSC 301739 ()
Mitozantrone (dihydrochloride) ()
NSC 301739 (dihydrochloride) ()
Mitoxantrone (NSC-301739)?2HCl ()
NSC-301739 2HCl ()
Mitoxantrone Dihcl ()
CL-232315 ()
Mitoxantrone Dihydrochloride ()
CL 232,315 ()
Misostol ()
NSC-279836 ()
Mitoxantrone (hydrochloride) ()
Mitoxantrone-d8 ()
P&D ID
PD004112
CAS
70476-82-3
65271-80-9
137635-96-2
70711-41-0
1189974-82-0
Tags
nuisance
natural product
probe
drug
available
Approved by
FDA
First approval
1987
Drug Status
investigational
approved
Drug indication
Antineoplastic
Non-hodgkin lymphoma
Solid tumour/cancer
Max Phase
Phase 4
Probe info
Probe selectivity
protein-selective
Probe type
P&D approved
calculated probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
7
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Marketed formulations may contain mitoxantrone hydrochloride (PubChem CID 5458171).
(GtoPdb)
DESCRIPTION
Selective CYP3A4 inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
DNA synthesis inhibitor
(LOPAC library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
50
Organisms
5
Compound Sets
34
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LINCS compound set
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
85
Molecular Weight
444.2
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
8
Rotatable Bonds
12
Ring Count
3
Aromatic Ring Count
2
cLogP
-0.14
TPSA
163.18
Fraction CSP3
0.36
Chiral centers
0.0
Largest ring
6.0
QED
0.14
Structural alerts
3
anthranil_one_A(38)
c:1:c:c:c:c(:c:1-[#7&!H0;!H1,!$([#7]-[#6]=[#8])])-[#6](-[#6]:[#6])=[#8]
PAINS Family B
quinone_A(370)
[!#6&!#1]=[#6]-1-[#6]=,:[#6]-[#6](=[!#6&!#1])-[#6]=,:[#6]-1
PAINS Family A
Intercalation
Nuisance compounds in cellular assays
Related compounds
Custom attributes
(extracted from source data)
MOA
Topoisomerase inhibitor
Inhibitor
Target
Tyrosine-protein kinase Fyn
DNA topoisomerase II alpha
DNA
Topo II
PKC
TOP2A
Endogenous Metabolite
Orthopoxvirus
Topoisomerase
Apoptosis related,COVID-19,PKC,Topoisomerase
Pathway
DNA Damage/DNA Repair
Cytoskeletal Signaling
Anti-infection
Apoptosis
Cell Cycle/DNA Damage
Epigenetics
Metabolic Enzyme/Protease
TGF-beta/Smad
Primary Target
DNA Topoisomerases
Indication
multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)
Disease Area
neurology/psychiatry, oncology, hematologic malignancy
Therapeutic Class
Anticancer Agents
Analgesics
Source data
